These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11519868)

  • 21. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer risks for BRCA1/2 carriers.
    Easton DF; Hopper JL; Thomas DC; Antoniou A; Pharoah PD; Whittemore AS; Haile RW
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622557
    [No Abstract]   [Full Text] [Related]  

  • 24. Lessons learned from genetic testing.
    Esserman L; Kaklamani V
    JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation.
    Sermijn E; Goelen G; Teugels E; Kaufman L; Bonduelle M; Neyns B; Poppe B; De Paepe A; De Grève J
    J Med Genet; 2004 Mar; 41(3):e23. PubMed ID: 14985394
    [No Abstract]   [Full Text] [Related]  

  • 26. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.
    Peshkin BN; Schwartz MD; Isaacs C; Hughes C; Main D; Lerman C
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1115-8. PubMed ID: 12376518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers.
    Dagan E; Goldblatt H
    Women Health; 2009 Jun; 49(4):263-79. PubMed ID: 19753503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
    Chang J; Elledge RM
    Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.
    Kelly K; Leventhal H; Marvin M; Toppmeyer D; Baran J; Schwalb M
    Cancer Control; 2004; 11(4):236-44. PubMed ID: 15284715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Bonadona V; Sinilnikova OM; Lenoir GM; Lasset C
    J Natl Cancer Inst; 2002 Oct; 94(20):1582-3; author reply 1583-4. PubMed ID: 12381714
    [No Abstract]   [Full Text] [Related]  

  • 31. Counseling high-risk women about breast cancer.
    LeGrazie B
    Oncology (Williston Park); 2011 Feb; 25(2 Suppl Nurse Ed):30-5. PubMed ID: 25373281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer risks for BRCA1/2 carriers.
    Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
    [No Abstract]   [Full Text] [Related]  

  • 34. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary breast cancer and genetic counseling in young women.
    Brunet J
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():7-9. PubMed ID: 20711663
    [No Abstract]   [Full Text] [Related]  

  • 37. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
    Loman N
    Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. StatBite: BRCA mutations in breast cancer patients under age 50 tested for mutations.
    J Natl Cancer Inst; 2010 Oct; 102(20):1530. PubMed ID: 20935267
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.